PATENT CLAIM ANALYSIS

Application Number: 16192347
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-09
Patent Classification: ["424", "186100"]

Abstract:
The disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins. The modified gL proteins remain intact and are able to form complexes with other CMV proteins.

Claim (Index 16):
A process of producing a recombinant Human Cytomegalovirus (HCMV) gL protein, or a complex-forming fragment thereof, comprising:\n (i) culturing an isolated host cell under a suitable condition,\n wherein said isolated host cell comprises a nucleic acid that encodes a recombinant HCMV gL protein, or a complex-forming fragment thereof, having a substitution mutation at a residue corresponding to A96, N97, S98, or a combination thereof, numbered according to SEQ ID NO: 1, \n thereby expressing said gL protein, or complex-forming fragment thereof; and (ii) harvesting said gL protein, or complex-forming fragment thereof, from the culture.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 98.0
- Lexical Diversity: 1.5
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15544730', '15522455', '14410461', '15596066', '13409987']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7979952966333573
- 35 USC 102 Novelty (BERT): 0.6392302803916535
- Combined Prediction Score: 0.782118795009187
- Mean Citation Score: 505.217634
- Max Citation Score: 663.51495
- Similarity Product: 561.8002522038728

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test